Fig. 2: rhIL-7-hyFc dramatically enhances UCART19 expansion, persistence, and anti-tumor efficacy in NSG mice engrafted with CD19+ RamosCBR-GFP cells in vivo.
a Experimental schema: NSG mice were injected via tail vein with 5 × 105 Ramos B lymphoma cells expressing click beetle red luciferase (CBR) and green fluorescent protein (GFP) (RamosCBR-GFP) on day −4, followed by 1 × 106 UCART19 on day 0, and rhIL-7-hyFc 10 mg/kg subcutaneously every 2 weeks for a total of three doses starting day +1 (n = 5 for no tx and rhIL-7-hyFc only groups; n = 10 for UCART19 and UCART19 + rhIL-7-hyFc groups). b Survival analysis for each treatment group. p Values were calculated using two-sided Wilcoxon test (UCART19 + rhIL-7-hyFc vs. UCART19 alone, p = 0.018). c Tumor burden measured by bioluminescent imaging (BLI). Data represent median ± 95% CI. Two-tailed p values were calculated using linear mixed model for repeated measurement data followed by post hoc multiple comparisons for between-group differences (UCART19 + rhIL-7-hyFc vs. UCART19 alone, p < 0.0001). d BLI images of individual mice treated with UCART19 only (left) and UCART19 + rhIL-7-hyFc (right). e, f Quantitative flow cytometric analyses of UCART19 expansion in peripheral blood. Representative FACS plots (e) and absolute UCART19/μl counts from peripheral blood (f). Each data point represents one mouse. Two-tailed p-values were calculated using a linear mixed model for repeated measurement data followed by post hoc multiple comparisons for between-group differences (UCART19 + rhIL-7-hyFc vs. UCART19 alone, p < 0.0001). Source data are provided as a Source data file. *p ≤ 0.05, ****p ≤ 0.0001.
